PV Bulletin

New e-Learning Modules for GCP Inspection Program by TGA

The Therapeutic Goods Administration (TGA) has launched interactive e-learning modules designed to clarify regulatory obligations related to Good Clinical Practice (GCP) inspections in Australia.

PV Impact Brief

Urgency: HighConfidence: high

What changed

The TGA introduced new e-learning modules specifically detailing the Good Clinical Practice (GCP) Inspection Program and the expectations for sponsors and investigators during inspections.

Why it matters

These educational resources aim to enhance the understanding of GCP compliance, which is critical for ensuring safety in clinical trials and maintaining regulatory standards.

Action needed

Stakeholders are encouraged to utilize the provided e-learning modules to improve their inspection readiness and compliance with GCP standards in Australia.

Relevant for
Regulatory Intelligence LeadPV Quality LeadQPPV
Processes impacted
Inspection ReadinessCountry Compliance
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Notice
Policy status
new
Publication date
2026-07-08
Policy change
The TGA has launched new interactive e-learning modules designed to help stakeholders understand their regulatory obligations, including a specific module on the TGA's Good Clinical Practice (GCP) Inspection Program. The module explains the purpose of the inspection program and what sponsors and investigators should expect during an inspection.

Key changes

Launch of the 'Getting started: TGA's Good Clinical Practice (GCP) Inspection Program' module; provides practical examples and context for compliance with GCP standards in Australia.

Affected workflows

Inspection ReadinessCountry Compliance

Responsible groups

Clinical OperationsQuality AssuranceRegulatory Affairs

PV impact

Sponsors and clinical trial teams can use this new official resource to improve inspection readiness for GCP audits. The guidance clarifies the TGA's approach to inspecting safety reporting and trial oversight, which is essential for compliance with clinical trial safety obligations.

View regulator source

Evidence and confidence

Confidence: highSource updated: Jul 8, 2026

Full briefing

Practical implication

Stakeholders are encouraged to utilize the provided e-learning modules to improve their inspection readiness and compliance with GCP standards in Australia.

The TGA's new interactive e-learning modules assist stakeholders, especially sponsors and clinical trial teams, in understanding their regulatory obligations and improving their readiness for GCP audits. The modules provide clarity on the inspection process and emphasize the importance of compliance with safety reporting and trial oversight requirements.

What changed: The TGA introduced new e-learning modules specifically detailing the Good Clinical Practice (GCP) Inspection Program and the expectations for sponsors and investigators during inspections.

Why it matters: These educational resources aim to enhance the understanding of GCP compliance, which is critical for ensuring safety in clinical trials and maintaining regulatory standards.

Practical implication: Stakeholders are encouraged to utilize the provided e-learning modules to improve their inspection readiness and compliance with GCP standards in Australia.

View original source

Published from the Firecrawl policy change extraction pipeline.

Related updates for your role

publicTherapeutics Goods Administration · Australia · Updated Jul 20, 2026

Updates on ISO 14155 and N=1 Therapeutics Discussed by TGA

Urgency: High

Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.

Inspection ReadinessICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicMedicines and Healthcare products Regulatory Agency (MHRA) · United Kingdom · Updated May 23, 2026

MHRA confirms UK clinical trial safety reporting guidance is effective

Urgency: High

Safety lead to: (1) perform a UK-clinical-trial safety reporting gap assessment against MHRA’s effective guidance sections (MedDRA coding; AE/SAE; RSI governance; SUSARs; annual safety reporting; USMs; serious breaches; temporary suspension), (2) update controlled SOPs/WIs and training records to reflect “effective” status as of 28 Apr 2026, and (3) document deviations/gaps and open CAPA where needed for ongoing UK trials and new submissions.

ICSRCountry ComplianceRegulatory Intelligence Lead
SOP Impact4 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Guidance
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Jul 20, 2026

CHMP Draft Agenda for Public Consultation on Thalassaemia and Sickle Cell Disease Guidelines

Urgency: High

Sponsors and MAHs must review and align safety data collection and reporting protocols with the newly adopted guidelines while preparing for implementation of PRAC recommendations stemming from this meeting.

Signal ManagementICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Agenda
Read impact briefarrow_forward
publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Urgency: High

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Checklist
Read impact briefarrow_forward